Tuesday, June 26, 2018 10:18:39 AM
March 31, 2018
reports cash and cash equivalents of $6,657,158
with 59.4 Million Shares outstanding
Average Share Price week before earning (divided by 12 for R/S)
?Mar? ?29?, ?2018 4.08 /12= 0.34
?Mar? ?28?, ?2018 4.44 /12= 0.37
?Mar? ?27?, ?2018 4.68 /12= 0.39
?Mar? ?26?, ?2018 4.68 /12= 0.39
?Mar? ?23?, ?2018 4.80 /12= 0.40
June 4, 2018
reverse split
12:1
4.9 Million Shares O/S
June 12, 2018
Closes on $18Million offering- Proceeds ~15-17 Mil?
18,280,000 shares plus warrants
+2,700,000 shares to agent
= 21 M shares at offering
21 million shares
+4.9 million shares
25.9 million shares New O/S
~$15 M Cash from offering plus cash reported Mar 31 plus 1 X earnings $505k
$15,000,000
$6,657,158
$ 505,000
________________
$22,762,158 divide by 25.9 M shares = 0.878 cents per share minus their burn rate over the last 3 months
Never bite off more than you can chew.
Recent CRDF News
- Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update • GlobeNewswire Inc. • 05/02/2024 08:05:00 PM
- Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update • GlobeNewswire Inc. • 04/25/2024 08:05:00 PM
- Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study • GlobeNewswire Inc. • 04/08/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:40:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:40:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:39:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:39:40 PM
- Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024 • GlobeNewswire Inc. • 03/06/2024 09:05:00 PM
- Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:07:00 PM
- Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC • GlobeNewswire Inc. • 02/29/2024 09:06:00 PM
- Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004) • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 09:00:21 PM
- Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 09:01:34 PM
- Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research • PR Newswire (US) • 01/17/2024 03:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 02:12:29 PM
- Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference • PR Newswire (US) • 11/20/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 08:06:30 PM
- Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update • PR Newswire (US) • 11/02/2023 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/02/2023 08:02:08 PM
- Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update • PR Newswire (US) • 10/26/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2023 08:07:11 PM
- Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy • PR Newswire (US) • 09/26/2023 08:05:00 PM
- Cardiff Oncology to Present at Upcoming Investor Conferences in September • PR Newswire (US) • 09/05/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM